ReviewRenal failure2025
Mechanisms of NLRP3 inflammasome in chronic kidney disease and the effects of traditional Chinese medicines.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The NLRP3 inflammasome in chronic kidney disease progression: systematic review of preclinical models reveals a critical gap in pyroptosis research and therapeutic translation.Molecular biology reports · 2026Pooled it
- N-Acetylcysteine Mitigates Renal Fibrosis by Modulating Inflammasome and Gluconeogenic Pathways Under Cardiometabolic Stress.Antioxidants (Basel, Switzerland) · 2026Article
- Programmed cell death in gouty nephropathy: molecular mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is characterized by a progressive decline of renal function, leading to multisystem problems and finally culminating in end-stage renal disease (ESRD). It has progressively emerged as a major global health issue. The nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome contributes to the inflammatory response chiefly by facilitating the secretion of inflammatory mediators, including interleukin-1β and interleukin-18. Recent studies have underscored the significance of NLRP3 inflammasome in renal pathology that is associated with CKD. In addition, a large number of studies have shown that traditional Chinese medicines (TCMS) can regulate NLRP3 through multiple targets and pathways, demonstrating significant potential in the treatment of CKD. These natural products offer advantages such as low costs and minimal side effects, making them a viable supplement or alternative to traditional treatment approaches for CKD. A literature review approach was employed to systematically search databases including Web of Science, ScienceDirect, and PubMed. Search keywords comprised 'Chronic kidney disease', 'NLRP3 inflammasome', 'traditional Chinese medicine', and their relevant synonyms/combinations. Through reviewing abstracts and full texts, the relationships between CKD and NLRP3 inflammasome, as well as the pharmacological mechanisms of TCMS, were classified and summarized. This study also explores the therapeutic potential of TCMS in regulating NLRP3 inflammasome. These findings might offer prospective diagnostic and therapeutic approaches for targeted or supplementary therapy of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.